Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 2 3 2021
medline: 29 6 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COVID-19 prognostic tools use only data present upon admission and do not incorporate changes occurring after admission. To develop the Severe COVID-19 Adaptive Risk Predictor (SCARP) (https://rsconnect.biostat.jhsph.edu/covid_trajectory/), a novel tool that can provide dynamic risk predictions for progression from moderate disease to severe illness or death in patients with COVID-19 at any time within the first 14 days of their hospitalization. Retrospective observational cohort study. Five hospitals in Maryland and Washington, D.C. Patients who were hospitalized between 5 March and 4 December 2020 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by nucleic acid test and symptomatic disease. A clinical registry for patients hospitalized with COVID-19 was the primary data source; data included demographic characteristics, admission source, comorbid conditions, time-varying vital signs, laboratory measurements, and clinical severity. Random forest for survival, longitudinal, and multivariate (RF-SLAM) data analysis was applied to predict the 1-day and 7-day risks for progression to severe disease or death for any given day during the first 14 days of hospitalization. Among 3163 patients admitted with moderate COVID-19, 228 (7%) became severely ill or died in the next 24 hours; an additional 355 (11%) became severely ill or died in the next 7 days. The area under the receiver-operating characteristic curve (AUC) for 1-day risk predictions for progression to severe disease or death was 0.89 (95% CI, 0.88 to 0.90) and 0.89 (CI, 0.87 to 0.91) during the first and second weeks of hospitalization, respectively. The AUC for 7-day risk predictions for progression to severe disease or death was 0.83 (CI, 0.83 to 0.84) and 0.87 (CI, 0.86 to 0.89) during the first and second weeks of hospitalization, respectively. The SCARP tool was developed by using data from a single health system. Using the predictive power of RF-SLAM and longitudinal data from more than 3000 patients hospitalized with COVID-19, an interactive tool was developed that rapidly and accurately provides the probability of an individual patient's progression to severe illness or death on the basis of readily available clinical information. Hopkins inHealth and COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response.

Sections du résumé

BACKGROUND
Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COVID-19 prognostic tools use only data present upon admission and do not incorporate changes occurring after admission.
OBJECTIVE
To develop the Severe COVID-19 Adaptive Risk Predictor (SCARP) (https://rsconnect.biostat.jhsph.edu/covid_trajectory/), a novel tool that can provide dynamic risk predictions for progression from moderate disease to severe illness or death in patients with COVID-19 at any time within the first 14 days of their hospitalization.
DESIGN
Retrospective observational cohort study.
SETTINGS
Five hospitals in Maryland and Washington, D.C.
PATIENTS
Patients who were hospitalized between 5 March and 4 December 2020 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by nucleic acid test and symptomatic disease.
MEASUREMENTS
A clinical registry for patients hospitalized with COVID-19 was the primary data source; data included demographic characteristics, admission source, comorbid conditions, time-varying vital signs, laboratory measurements, and clinical severity. Random forest for survival, longitudinal, and multivariate (RF-SLAM) data analysis was applied to predict the 1-day and 7-day risks for progression to severe disease or death for any given day during the first 14 days of hospitalization.
RESULTS
Among 3163 patients admitted with moderate COVID-19, 228 (7%) became severely ill or died in the next 24 hours; an additional 355 (11%) became severely ill or died in the next 7 days. The area under the receiver-operating characteristic curve (AUC) for 1-day risk predictions for progression to severe disease or death was 0.89 (95% CI, 0.88 to 0.90) and 0.89 (CI, 0.87 to 0.91) during the first and second weeks of hospitalization, respectively. The AUC for 7-day risk predictions for progression to severe disease or death was 0.83 (CI, 0.83 to 0.84) and 0.87 (CI, 0.86 to 0.89) during the first and second weeks of hospitalization, respectively.
LIMITATION
The SCARP tool was developed by using data from a single health system.
CONCLUSION
Using the predictive power of RF-SLAM and longitudinal data from more than 3000 patients hospitalized with COVID-19, an interactive tool was developed that rapidly and accurately provides the probability of an individual patient's progression to severe illness or death on the basis of readily available clinical information.
PRIMARY FUNDING SOURCE
Hopkins inHealth and COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response.

Identifiants

pubmed: 33646849
doi: 10.7326/M20-6754
pmc: PMC7934337
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

777-785

Subventions

Organisme : NIAID NIH HHS
ID : K08 AI143391
Pays : United States

Auteurs

Shannon Wongvibulsin (S)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Brian T Garibaldi (BT)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Annukka A R Antar (AAR)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Jiyang Wen (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

Mei-Cheng Wang (MC)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

Amita Gupta (A)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Robert Bollinger (R)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Yanxun Xu (Y)

Johns Hopkins University, Baltimore, Maryland (Y.X., K.W.).

Kunbo Wang (K)

Johns Hopkins University, Baltimore, Maryland (Y.X., K.W.).

Joshua F Betz (JF)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

John Muschelli (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

Karen Bandeen-Roche (K)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

Scott L Zeger (SL)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.W., M.W., J.F.B., J.M., K.B., S.L.Z.).

Matthew L Robinson (ML)

Johns Hopkins University School of Medicine, Baltimore, Maryland (S.W., B.T.G., A.A.A., A.G., R.B., M.L.R.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH